PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced

Cancer Letters

Volumn 348, Issue 1-2, 2014, Pages 38-49

  Jebahi, Abdelghani ^a,b,c   Villedieu, Marie ^a,b,c,d   Pétigny Lechartier, Cécile ^a,b,c   Brotin, Emilie ^a,b   Louis, Marie Hélène ^a,b,c   Abeilard, Edwige ^a,b,c   Giffard, Florence ^a,b,c   Guercio, Marika ^a,b   Briand, Mélanie ^a,b,c   Gauduchon, Pascal ^a,b,c   Lheureux, Stéphanie ^a,b,c   Poulain, Laurent ^a,b,c  

^a NORMANDIE UNIVERSITÉ   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c Francois Baclesse Comprehensive Cancer Centre   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

ABT 737; Bim; ERK1 2; Mcl 1; NVP BEZ235; Ovarian cancer

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PUMA PROTEIN; RNA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CARCINOMA CELL; CELL PROLIFERATION; DRUG MECHANISM; DRUG SENSITIZATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

ABT-737; BIM; ERK1/2; MCL-1; NVP-BEZ235; OVARIAN CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MEMBRANE PROTEINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOLINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SULFONAMIDES; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84900475912     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.001     Document Type: Article

References (53)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64(2014):9-29.
2. Coleman R.L., Monk B.J., Sood A.K., Herzog T.J. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 2013, 10:211-224.
3. Juin P., Geneste O., Gautier F., Depil S., Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat. Rev. Cancer 2013, 13:455-465.
4. Brotin E., Meryet-Figuiere M., Simonin K., Duval R.E., Villedieu M., Leroy-Dudal J., Saison-Behmoaras E., Gauduchon P., Denoyelle C., Poulain L. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int. J. Cancer 2010, 126:885-895.
5. Simonin K., N'diaye M., Lheureux S., Loussouarn C., Dutoit S., Briand M., Giffard F., Brotin E., Blanc-Fournier C., Poulain L. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis 2013, 18:492-508.
6. Simonin K., Brotin E., Dufort S., Dutoit S., Goux D., N'diaye M., Denoyelle C., Gauduchon P., Poulain L. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol. Cancer Ther. 2009, 8:3162-3170.
7. Davids M.S., Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J. Clin. Oncol. 2012, 30:3127-3135.
8. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
9. Gandhi L., Camidge D.R., Ribeiro de O.M., Bonomi P., Gandara D., Khaira D., Hann C.L., McKeegan E.M., Litvinovich E., Hemken P.M., Dive C., Enschede S.H., Nolan C., Chiu Y.L., Busman T., Xiong H., Krivoshik A.P., Humerickhouse R., Shapiro G.I., Rudin C.M. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 2011, 29:909-916.
10. Rudin C.M., Hann C.L., Garon E.B., Ribeiro de O.M., Bonomi P.D., Camidge D.R., Chu Q., Giaccone G., Khaira D., Ramalingam S.S., Ranson M.R., Dive C., McKeegan E.M., Chyla B.J., Dowell B.L., Chakravartty A., Nolan C.E., Rudersdorf N., Busman T.A., Mabry M.H., Krivoshik A.P., Humerickhouse R.A., Shapiro G.I., Gandhi L. Phase II study of single-agent Navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 2012, 18:3163-3169.
11. Kline M.P., Rajkumar S.V., Timm M.M., Kimlinger T.K., Haug J.L., Lust J.A., Greipp P.R., Kumar S. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007, 21:1549-1560.
12. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.X., Sneed T., Verhaegen M., Soengas M., Ruvolo V.R., McQueen T., Schober W.D., Watt J.C., Jiffar T., Ling X., Marini F.C., Harris D., Dietrich M., Estrov Z., McCubrey J., May W.S., Reed J.C., Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
13. Tagscherer K.E., Fassl A., Campos B., Farhadi M., Kraemer A., Bock B.C., Macher-Goeppinger S., Radlwimmer B., Wiestler O.D., Herold-Mende C., Roth W. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008, 27:6646-6656.
14. Li R., Zang Y., Li C., Patel N.S., Grandis J.R., Johnson D.E. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol. Pharmacol. 2009, 75:1231-1239.
15. Chen S., Dai Y., Harada H., Dent P., Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007, 67:782-791.
16. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D.M., Vernetti L.A., Fesik S.W., Shen Y. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007, 26:3972-3979.
17. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
18. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
19. Konopleva M., Milella M., Ruvolo P., Watts J.C., Ricciardi M.R., Korchin B., McQueen T., Bornmann W., Tsao T., Bergamo P., Mak D.H., Chen W., McCubrey J., Tafuri A., Andreeff M. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2012, 26:778-787.
20. Thomas L.W., Lam C., Edwards S.W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010, 584:2981-2989.
21. Wang J.M., Chao J.R., Chen W., Kuo M.L., Yen J.J., Yang-Yen H.F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell Biol. 1999, 19:6195-6206.
22. Hsieh A.C., Costa M., Zollo O., Davis C., Feldman M.E., Testa J.R., Meyuhas O., Shokat K.M., Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17:249-261.
23. Mills J.R., Hippo Y., Robert F., Chen S.M., Malina A., Lin C.J., Trojahn U., Wendel H.G., Charest A., Bronson R.T., Kogan S.C., Nadon R., Housman D.E., Lowe S.W., Pelletier J. MTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. U.S.A 2008, 105:10853-10858.
24. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21:749-760.
25. Qi X.J., Wildey G.M., Howe P.H. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J. Biol. Chem. 2006, 281:813-823.
26. Dijkers P.F., Medema R.H., Lammers J.W., Koenderman L., Coffer P.J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 2000, 10:1201-1204.
27. You H., Pellegrini M., Tsuchihara K., Yamamoto K., Hacker G., Erlacher M., Villunger A., Mak T.W. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J. Exp. Med. 2006, 203:1657-1663.
28. Qian J., Zou Y., Rahman J.S., Lu B., Massion P.P. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol. Cancer Ther. 2009, 8:101-109.
29. Rahmani M., Aust M.M., Attkisson E., Williams D.C., Ferreira-Gonzalez A., Grant S. Dual Inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K Inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res. 2013, 73:1340-1351.
30. Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011) 609-615.
31. Laplante M., Sabatini D.M. MTOR signaling in growth control and disease. Cell 2012, 149:274-293.
32. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De P.A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7:1851-1863.
33. Cho D.C., Cohen M.B., Panka D.J., Collins M., Ghebremichael M., Atkins M.B., Signoretti S., Mier J.W. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 2010, 16:3628-3638.
34. Ma B.B., Lui V.W., Hui C.W., Lau C.P., Wong C.H., Hui E.P., Ng M.H., Cheng S.H., Tsao S.W., Tsang C.M., Cheung C.S., Ho K., Chan A.T. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2013, 343:24-32.
35. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di C.S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
36. Zang C., Eucker J., Liu H., Muller A., Possinger K., Scholz C.W. Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Cancer Lett. 2012, 339. 2988-297.
37. Montero J.C., Chen X., Ocana A., Pandiella A. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol. Cancer Ther. 2012, 11:1342-1352.
38. Santiskulvong C., Konecny G.E., Fekete M., Chen K.Y., Karam A., Mulholland D., Eng C., Wu H., Song M., Dorigo O. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin. Cancer Res. 2011, 17:2373-2384.
39. Poulain L., Lincet H., Duigou F., Deslandes E., Sichel F., Gauduchon P., Staedel C. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int. J. Cancer 1998, 78:454-463.
40. Ke N., Wang X., Xu X., Abassi Y.A. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol. Biol. 2011, 740:33-43.
41. Luciano F., Jacquel A., Colosetti P., Herrant M., Cagnol S., Pages G., Auberger P. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003, 22:6785-6793.
42. Muller A., Zang C., Chumduri C., Dorken B., Daniel P.T., Scholz C.W. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Int. J. Cancer 2013, 133:1813-1824.
43. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.M., Garcia-Echeverria C., Wong K.K., Engelman J.A. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. U.S.A 2009, 106:19503-19508.
44. Bean G.R., Ganesan Y.T., Dong Y., Takeda S., Liu H., Chan P.M., Huang Y., Chodosh L.A., Zambetti G.P., Hsieh J.J., Cheng E.H. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci. Signal 2013, 6:ra20.
45. Kim A., Lee J.E., Lee S.S., Kim C., Lee S.J., Jang W.S., Park S. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int. J. Cancer 2013, 133:984-996.
46. Bijman M.N., van Berkel M.P., Kok M., Janmaat M.L., Boven E. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines. Anticancer Drugs 2009, 20:450-460.
47. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer cell 2012, 21:227-239.
48. Tan N., Wong M., Nannini M.A., Hong R., Lee L.B., Price S., Williams K., Savy P.P., Yue P., Sampath D., Settleman J., Fairbrother W.J., Belmont L.D. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Mol. Cancer Ther. 2013, 12:853-864.
49. Corcoran R.B., Cheng K.A., Hata A.N., Faber A.C., Ebi H., Coffee E.M., Greninger P., Brown R.D., Godfrey J.T., Cohoon T.J., Song Y., Lifshits E., Hung K.E., Shioda T., Dias-Santagata D., Singh A., Settleman J., Benes C.H., Mino-Kenudson M., Wong K.K., Engelman J.A. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
50. Cragg M.S., Jansen E.S., Cook M., Harris C., Strasser A., Scott C.L. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest 2008, 118:3651-3659.
51. Sale M.J., Cook S.J. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Biochem. J. 2013, 450:285-294.
52. Ewings K.E., Hadfield-Moorhouse K., Wiggins C.M., Wickenden J.A., Balmanno K., Gilley R., Degenhardt K., White E., Cook S.J. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 2007, 26:2856-2867.
53. Rahmani M., Anderson A., Habibi J.R., Crabtree T.R., Mayo M., Harada H., Ferreira-Gonzalez A., Dent P., Grant S. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 2009, 114:4507-4516.